pIPELINE

RARE DISORDERS AND INFECTIOnS DISEAsES

Pharmaceutical Product Pipeline

 ​Revive is building a pharmaceutical product portfolio targeting rare disorders and infectious diseases.

PHARMACEUTICAL STRATEGY

Clinical development of Bucillamine and Psilocybin

targeting rare disorders and infectious diseases

novel Uses, formulations and delivery system

targeting FDA designations: Orphan, Fast track, breakthrough therapy and rare pediatric diseases

FORMULATION & DELIVERY TECHNOLOGY

  • Delivering naturally extracted and synthetic psilocybin and cannabinoids
  • PSILOCYBIN – Prescise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips
    • Releases (rapid, controlled, sustained), improved bioavailability, no first-pass etabolism
  • CANNABIDIOL – Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects
    • Tannin (plant-based) – antibacterial, antifungal, antioxidant and wound healing
    • Chistosan (shrimp-based) – blood-clotting and antimicrobial properties

PRODUCT PIPELINE

Focus on Infectious Diseases, Rare Disorders, Mental Illness
Product

Bucillamine
(Oral Tablet)

Indication
Infectious Diseases
(Covid-19)
Stage of Development

Completed Phase 3

Regulatory Status

Determining next steps and international opps

Product

Bucillamine
(Intravenous)

Indication

Rare Inflammatory Disorders
Ischemia-reperfusion

Stage of Development

Phase 1/2

Regulatory Status

IND filing for clinical study

Product

Diagnostic Rapid Test

Indication

Long Covid

Stage of Development

Pre-Commerical prototype

Regulatory Status

Preparing submission for FDA approval pathway

Product

Oral Psilocybin
(Oral Capsule)

Indication

Substance Use Disorder
Methamphetamine

Stage of Development

Phase 1/2

Regulatory Status

Preparing end-of-Phase 2 meeting with FDA

Product

Psilocybin
(Microneedle Patch)

Indication

Mental Illness
Depression, Anxiety

Stage of Development

IND-enabling

Regulatory Status

IND filing for clinical study

Bucillamine
(Oral Tabelet)

Infectious Diseases
(Covid-19)

Completed Phase 3

Determining next steps and international opps

Bucillamine
(Intravenous)

Rare Inflammatory Disorders
 Ischemia-reperfusion

Phase 1/2

IND filing for clinical study

Diagnostic Rapid Test

Long Covid

Pre-commercial prototype

Preparing submission for FDA approval pathway

Oral Psilocybin
(Oral Capsule)

Substance Use Disorder
Methamphetamine

Phase 1/2

Preparing end-of-Phase 2 meeting with FDA

Psilocybin
(Microneedle Patch)

Mental Illness
Depression, Anxiety

IND-enabling

IND filing for clinical study

As for its rare disease pharmaceutical product pipeline, Revive has been granted by the U.S. Food and Drug Administration (“FDA”) two orphan drug designations for cannabidiol (“CBD”) in the treatment of autoimmune hepatitis, a rare liver disease, and CBD in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation, such as liver, kidney, heart and lung.